CVRx will present at Canaccord Genuity's conference on August 11, discussing its neuromodulation device for heart failure.
Quiver AI Summary
CVRx, Inc., a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 1:00 p.m. ET. The presentation will be available via live webcast on the company's investor relations website, with an archived version accessible afterward. CVRx is known for its Barostim technology, the first FDA-approved device that uses neuromodulation to alleviate heart failure symptoms. Barostim delivers electrical pulses to baroreceptors in the carotid artery to help restore balance to the autonomic nervous system, and it has received both FDA Breakthrough Device designation and CE Mark approval for use in certain patient populations. For further details, visit the CVRx website.
Potential Positives
- CVRx is presenting at Canaccord Genuity's 46th Annual Growth Conference, highlighting its visibility and credibility in the financial community.
- The company's Barostim device is the first FDA-approved technology using neuromodulation for heart failure, showcasing innovation in the medical device sector.
- Barostim has received FDA Breakthrough Device designation, indicating its potential to significantly improve patient care for heart failure.
- CVRx has achieved compliance with EU Medical Device Regulation and holds CE Mark approval, allowing for broader market access in the European Economic Area.
Potential Negatives
- None
FAQ
What is CVRx, Inc. known for?
CVRx, Inc. is known for developing innovative neuromodulation solutions for cardiovascular diseases, particularly its Barostim device for heart failure.
When will CVRx present at the Canaccord Genuity Conference?
CVRx will present at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, at 1:00 p.m. (ET).
How can I access the live webcast of the CVRx presentation?
The live webcast of the CVRx presentation can be accessed at ir.cvrx.com during the event.
What is Barostim and its purpose?
Barostim is an implantable device that uses neuromodulation to improve heart failure symptoms by restoring balance to the autonomic nervous system.
What approvals does Barostim have?
Barostim is FDA-approved for heart failure, has received Breakthrough Device designation, and holds CE Mark approval in Europe.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CVRX Insider Trading Activity
$CVRX insiders have traded $CVRX stock on the open market 7 times in the past 6 months. Of those trades, 2 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $CVRX stock by insiders over the last 6 months:
- MUDIT K. JAIN has made 2 purchases buying 47,400 shares for an estimated $300,376 and 0 sales.
- KEVIN HYKES (PRES & CEO) sold 7,763 shares for an estimated $61,348
- ROBERT ALLEN JOHN (Chief Revenue Officer) sold 3,964 shares for an estimated $31,325
- JARED OASHEIM (CHIEF FINANCIAL OFFICER) sold 1,744 shares for an estimated $13,781
- PAUL VERRASTRO (CHIEF MKTG & STRAT OFFICER) sold 1,284 shares for an estimated $10,146
- PHILIP B. ADAMSON (Chief Medical Officer) sold 1,262 shares for an estimated $9,973
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CVRX Hedge Fund Activity
We have seen 45 institutional investors add shares of $CVRX stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROYAL BANK OF CANADA added 696,334 shares (+6559.3%) to their portfolio in Q1 2026, for an estimated $6,587,319
- CITADEL ADVISORS LLC removed 278,876 shares (-91.3%) from their portfolio in Q1 2026, for an estimated $2,638,166
- MORGAN STANLEY removed 241,277 shares (-63.4%) from their portfolio in Q1 2026, for an estimated $2,282,480
- JANE STREET GROUP, LLC removed 225,349 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,131,801
- BALYASNY ASSET MANAGEMENT L.P. removed 184,131 shares (-22.6%) from their portfolio in Q1 2026, for an estimated $1,741,879
- MAIRS & POWER INC removed 142,456 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,347,633
- MILLENNIUM MANAGEMENT LLC removed 125,540 shares (-90.2%) from their portfolio in Q1 2026, for an estimated $1,187,608
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at Canaccord Genuity's 46 th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The Company's presentation will begin at 1:00 p.m. (ET).
A live webcast of the event can be found at
ir.cvrx.com
. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
[email protected]
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
[email protected]
